SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Catalyst Pharmaceutical Partners, Inc. Announces Commencement of CPP-109 Investigator-Sponsored Study in Patients With Treatment Refractory Tourette's Disorder